Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee

Journal of Rheumatology

Volumn 36, Issue 6, 2009, Pages 1290-1297

  Karlsson, Jon ^a   Pivodic, Aldina ^b   Aguirre, Diana ^b   Schnitzer, Thomas J ^c,d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NicOx SA   (France)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cyclooxygenase inhibiting nitric oxide donATOR; Naproxcinod; Osteoarthritis; Rofecoxib

Indexed keywords

NAPROXCINOD; NITRIC OXIDE DONOR; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIP; HUMAN; JOINT STIFFNESS; KNEE; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; OSTEOARTHRITIS; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; NITRIC OXIDE DONORS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67149147431     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081011     Document Type: Article

References (34)

1. Felson D. Epidemiology of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. Oxford: Oxford University Press; 2003:9-16.
2. Gupta S, Hawker GA, Laporte A, Croxford R, Coyte PC. The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. Rheumatology 2005;44:1531-1537 (Pubitemid 41742470)
3. Leveille SG. Musculoskeletal aging. Curr Opin Rheumatol 2004;16:114-118 (Pubitemid 38280945)
4. Jinks C, Jordan K, Croft P. Disabling knee pain - another consequence of obesity: Results from a prospective cohort study. BMC Public Health 2006;6:258. (Pubitemid 44727152)
5. Hirschowitz BI. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994;2:207-223
6. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. Br Med J 1990;300:278-284
7. Myerson RM. NSAID-associated gastroduodenal damage. J Pharm Med 1992;2:277-284
8. Ignarro LJ. Nitric oxide as a unique signalling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53:503-514 (Pubitemid 36014797)
9. Muscara MN, McKnight W, Del Soldato P, Wallace JL. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci 1998;62:PL235-240. (Pubitemid 28177436)
10. Rudd MA. Nitric oxide and hypertension. In: Loscalzo J, Vita JA, editors. Contemporary cardiology, nitric oxide and the cardiovascular system. Totawa, NJ: Humana Press; 2000:227-246
11. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005;26:33-65. (Pubitemid 40250164)
12. Stokes GS, Bune AJ, Huon N, Barin ES. Long-term effectiveness of extended-release nitrates for the treatment of systolic hypertension. Hypertension 2005;45:380-384 (Pubitemid 40315807)
13. Muscara MN, McKnight W, Lovren F, Triggle CR, Cirino G, Wallace JL. Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am J Physiol Heart Circ Physiol 2000;279:H528-H535. (Pubitemid 30672764)
14. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
15. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC™: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-1840 (Pubitemid 19037656)
16. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC™: a health status instrument for measuring clinically-important patient relevant outcomes following total hip or knee arthroplasty in osteoarthritis. J Orthop Rheumatol 1988;1:95-108.
17. Bellamy N. Pain assessment in OA: Experience with the WOMAC™ osteoarthritis index. Semin Arthritis Rheum 1989;18:14-17 (Pubitemid 19147641)
18. Skoglund LA, Skjelbred P, Fyllingen G. Analgesic efficacy of acetaminophen 1000 mg, acetaminophen 2000 mg, and the combination of acetaminophen 1000 mg and codeine phosphate 60 mg versus placebo in acute postoperative pain. Pharmacotherapy 1991;11:364-369
19. Gotzsche PC. Review of dose-response studies of NSAIDs in rheumatoid arthritis. Dan Med Bull 1989;36:395-399 (Pubitemid 19229793)
20. Seymour RA, Ward-Booth P, Kelly PJ. Evaluation of different doses of soluble ibuprofen and ibuprofen tablets in postoperative dental pain. Br J Oral Maxillofac Surg 1996;34:110-114 (Pubitemid 26067445)
21. Eisenberg E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994;12:2756-2765 (Pubitemid 24379666)
22. Schnitzer TJ, Kivitz AJ, Lipetz RS, Sanders N, Hee A. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum 2005;53:827-837 (Pubitemid 41811122)
23. Lohmander LS, McKeith D, Svensson O, et al; STAR Multinational Study Group. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005;64;449-456
24. Fagerholm U, Bjornsson MA. Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. J Pharm Pharmacol 2005;57:1539-1554 (Pubitemid 41752268)
25. Davies NM, Røseth AG, Appleyard CB, et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 1997;11:69-79. (Pubitemid 27067336)
26. Fiorucci S, Di Lorenzo A, Renga B, et al. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J Pharmacol Exp Ther 2004;311:1264-1271 (Pubitemid 39612736)
27. Hawkey CJ, Jones JI, Atherton CT, et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003;52:1537-1542 (Pubitemid 37363434)
28. Wilder-Smith CH, Jonzon B, Fornstedt-Wallin B, Hedman A, Karlsson P. Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects. Scand J Gastroenterol 2006;41:264-273 (Pubitemid 43311036)
29. Miller MR, Okubo K, Roseberry MJ, Webb DJ, Megson IL. Extracellular nitric oxide release mediates soluble guanylate cyclase-independent vasodilator action of spermine NONOate: comparison with other nitric oxide donors in isolated rat femoral arteries. J Cardiovasc Pharmacol 2004;43:440-451 (Pubitemid 38270612)
30. Crane MS, Rossi AG, Megson IL. A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations. Br J Pharmacol 2005;144:849-859 (Pubitemid 40516124)
31. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999;43:580-594 (Pubitemid 29369257)
32. Bath PM. The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. Eur J Pharmacol 1993;45:53-58 (Pubitemid 23225957)
33. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95. (Pubitemid 33753522)
34. Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002;72:50-61. (Pubitemid 34833187)